UK Price Scheme Changes To Cost Pharmaceutical Industry £33m
Executive Summary
The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.
You may also be interested in...
New UK Price Deal To Save NHS £930m & Speed Up Access To Innovation
The revised PPRS, which is expected to take effect at the beginning of 2019, will implement a 2% cap on the growth in sales of branded medicines to the NHS that should result in substantial savings on medicines spending. It also provides for faster NICE appraisals for non-cancer drugs, and more flexibility in commercial discussions between companies and the health department.
Changes To UK Price Scheme To Hit Profits, Biosimilar Launches
Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.
Changes To UK Price Scheme To Hit Profits, Biosimilar Launches
Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.